SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported) March 8, 2000
Discovery Laboratories, Inc.
- --------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in its Charter)
Delaware 000-26422 94-3171943
- --------------------------------------------------------------------------------
(State or Other (Commission (I.R.S. Employer
Jurisdiction of File Number) Identification
incorporation) No.)
350 Main Street, Suite 307, Doylestown, Pennsylvania 18901
------------------------------------------------------------------------------
(Address of Principal Executive Offices (Zip Code)
(Registrant's Telephone Number, Including Area Code) (215) 340-4699
- --------------------------------------------------------------------------------
(Former Name or Former Address, If Changed Since Last Report.)
931039.1
ITEM 5. Other Events.
On March 8, 2000, Registrant issued a press release to announce
that it has received a conversion notice from Johnson & Johnson to convert the
2,039 shares of Series C Convertible Preferred Stock owned by it into 398,186
shares of Common Stock.
ITEM 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits.
ExhibitDescription
------------------
99.1 Press Release, dated March 8, 2000.
931039.1
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
DISCOVERY LABORATORIES, INC.
By: /s/ Robert J. Capetola, Ph.D.
-------------------------------
Name: Robert J. Capetola, Ph.D.
Title: President and Chief Executive
Officer
Date: March 19, 2000
931039.1